INS and Parkinson disease: Reduced expression of insulin receptor mRNAs [71] and decreased insulin action (insulin resistance) have been documented in the CNS of PD patients [72, 73] and there is evidence that this has a direct impact on dopaminergic function, accelerating the progressive neuronal degeneration and the development of PD deficits [74].